PE20121180A1 - (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer - Google Patents

(heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer

Info

Publication number
PE20121180A1
PE20121180A1 PE2012000315A PE2012000315A PE20121180A1 PE 20121180 A1 PE20121180 A1 PE 20121180A1 PE 2012000315 A PE2012000315 A PE 2012000315A PE 2012000315 A PE2012000315 A PE 2012000315A PE 20121180 A1 PE20121180 A1 PE 20121180A1
Authority
PE
Peru
Prior art keywords
methyl
thiohidantoins
heteroarylmetil
substituted
cancer drugs
Prior art date
Application number
PE2012000315A
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Lucking
Arwed Cleve
Bernard Haendler
Gimenez Hortensia Faus
Silke Kohr
Horst Irlbacher
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20121180A1 publication Critical patent/PE20121180A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2012000315A 2009-09-11 2010-08-28 (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer PE20121180A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17

Publications (1)

Publication Number Publication Date
PE20121180A1 true PE20121180A1 (es) 2012-08-24

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000315A PE20121180A1 (es) 2009-09-11 2010-08-28 (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer

Country Status (28)

Country Link
US (1) US20120251551A1 (OSRAM)
EP (1) EP2475653A1 (OSRAM)
JP (1) JP2013504523A (OSRAM)
KR (1) KR20120065396A (OSRAM)
CN (1) CN102639523A (OSRAM)
AR (1) AR078166A1 (OSRAM)
AU (1) AU2010294588A1 (OSRAM)
BR (1) BR112012005526A2 (OSRAM)
CA (1) CA2773591A1 (OSRAM)
CL (1) CL2012000623A1 (OSRAM)
CO (1) CO6511228A2 (OSRAM)
CR (1) CR20120113A (OSRAM)
CU (1) CU20120042A7 (OSRAM)
DO (1) DOP2012000063A (OSRAM)
EA (1) EA201200473A1 (OSRAM)
EC (1) ECSP12011716A (OSRAM)
IL (1) IL218390A0 (OSRAM)
IN (1) IN2012DN02081A (OSRAM)
MA (1) MA33566B1 (OSRAM)
MX (1) MX2012002977A (OSRAM)
NZ (1) NZ598643A (OSRAM)
PE (1) PE20121180A1 (OSRAM)
PH (1) PH12012500497A1 (OSRAM)
SG (1) SG178919A1 (OSRAM)
TN (1) TN2012000108A1 (OSRAM)
TW (1) TW201111378A (OSRAM)
UY (1) UY32882A (OSRAM)
WO (1) WO2011029537A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130184A1 (es) 2010-02-17 2013-03-09 Takeda Pharmaceutical Compuesto heterociclico
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
PL2935303T3 (pl) 2012-12-21 2021-10-04 Janssen Biopharma, Inc. 4'-fluoronukleozydy, 4'-fluoronukleotydy i ich analogi do leczenia HCV
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
SMT202300014T1 (it) * 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
JP6888000B2 (ja) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3057892A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2018211442A1 (en) 2017-05-18 2018-11-22 Pi Industries Ltd. Formimidamidine compounds useful against phytopathogenic microorganisms
WO2019158517A1 (en) 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
WO2020209933A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
WO2021150603A1 (en) * 2020-01-21 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
WO2003087061A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
EP1656357A1 (en) 2003-07-02 2006-05-17 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
RU2006110561A (ru) 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) Соединения бензоимидазола
WO2005061463A1 (en) 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
ATE503746T1 (de) 2004-08-03 2011-04-15 Chugai Pharmaceutical Co Ltd Neue imidazolidinderivate
CN101048381A (zh) * 2004-09-09 2007-10-03 中外制药株式会社 新型四氢咪唑衍生物及其用途
CA2588463A1 (en) 2004-12-03 2006-06-08 Matthias Heinrich Nettekoven 3-substituted pyridine derivatives as h3 antagonists
KR101332924B1 (ko) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
MA33566B1 (fr) 2012-09-01
CN102639523A (zh) 2012-08-15
TN2012000108A1 (en) 2013-09-19
US20120251551A1 (en) 2012-10-04
WO2011029537A1 (en) 2011-03-17
DOP2012000063A (es) 2012-05-15
MX2012002977A (es) 2012-04-30
CA2773591A1 (en) 2011-03-17
BR112012005526A2 (pt) 2016-04-26
EA201200473A1 (ru) 2012-10-30
TW201111378A (en) 2011-04-01
CL2012000623A1 (es) 2012-09-14
CR20120113A (es) 2012-05-02
CO6511228A2 (es) 2012-08-31
NZ598643A (en) 2013-10-25
KR20120065396A (ko) 2012-06-20
PH12012500497A1 (en) 2012-10-22
UY32882A (es) 2011-04-29
EP2475653A1 (en) 2012-07-18
CU20120042A7 (es) 2012-06-21
ECSP12011716A (es) 2012-04-30
AU2010294588A1 (en) 2012-04-05
AR078166A1 (es) 2011-10-19
SG178919A1 (en) 2012-04-27
JP2013504523A (ja) 2013-02-07
IN2012DN02081A (OSRAM) 2015-08-21
IL218390A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
PE20121180A1 (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20170325A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll
PE20160654A1 (es) Compuestos de inhibidor de autotaxina
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
MX2011010451A (es) Derivados de oxadiazol.
PE20151748A1 (es) Inhibidores de bace1
PE20141823A1 (es) Derivados de tetrahidro-quinazolinona
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
CR10850A (es) Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico

Legal Events

Date Code Title Description
FD Application declared void or lapsed